Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 8, 2008, Pages 2898-2904

  Lim, Tze Peng ^a   Ledesma, Kimberly R ^b   Chang, Kai Tai ^b   Hou, Jing Guo ^b   Kwa, Andrea L ^a   Nikolaou, Michael ^b   Quinn, John P ^c   Prince, Randall A ^b   Tam, Vincent H ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b UNIVERSITY OF HOUSTON   (United States)

^c RUSH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CEFEPIME; LEVOFLOXACIN; MOXIFLOXACIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL MODEL; HOLLOW FIBER; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIMULATION; VALIDATION PROCESS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMIKACIN; ANTI-INFECTIVE AGENTS; CEPHALOSPORINS; DRUG ANTAGONISM; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN;

EID: 48749095699     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01309-07     Document Type: Article

References (29)

1. Barbhaiya, R. H., S. T. Forgue, C. R. Gleason, C. A. Knupp, K. A. Pittman, D. J. Weidler, H. Movahhed, J. Tenney, and R. R. Martin. 1992. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob. Agents Chemother. 36:552-557.
2. Blaser, J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130.
3. Bonapace, C. R., R. L. White, L. V. Friedrich, and J. A. Bosso. 2000. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods. Diagn. Microbiol. Infect. Dis. 38:43-50.
4. Bonomo, R. A., and D. Szabo. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43(Suppl. 2):S49-S56.
5. Boucher, A. N., and V. H. Tam. 2006. Mathematical formulation of additivity for antimicrobial agents. Diagn. Microbiol. Infect. Dis. 55:319-325.
6. Cappelletty, D. M., and M. J. Rybak. 1996. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:677-683.
7. Centers for Disease Control and Prevention. 2004. Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb. Mortal. Wkly. Rep. 53:1063-1066.
8. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial testing: 17th informational supplement. CLSI M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
9. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, University of Southern California, Los Angeles.
10. Drusano, G. L., D. Z. D'Argenio, W. Symonds, P. A. Bilello, J. McDowell, B. Sadler, A. Bye, and J. A. Bilello. 1998. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob. Agents Chemother. 42:2153-2159.
11. Gaynes, R., and J. R. Edwards. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
12. Hilf, M., V. L. Yu, J. Sharp, J. J. Zuravleff, J. A. Korvick, and R. R. Muder. 1989. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am. J. Med. 87:540-546.
13. Kuo, L. C., C. C. Lai, C. H. Liao, C. K. Hsu, Y. L. Chang, C. Y. Chang, and P. R. Hsueh. 2007. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin. Microbiol. Infect. 13:196-198.
14. Kwa, A. L., J. G. Low, E. Lee, A. Kurup, H. L. Chee, and V. H. Tam. 2007. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn. Microbiol. Infect. Dis. 58:99-104.
15. Levin, A. S., A. A. Barone, J. Penco, M. V. Santos, I. S. Marinho, E. A. Arruda, E. I. Manrique, and S. F. Costa. 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28:1008-1011.
16. Lim, T. P., K. R. Ledesma, K. T. Chang, A. L. Kwa, and V. H. Tam. 2007. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-8.
17. Lolans, K., T. W. Rice, L. S. Munoz-Price, and J. P. Quinn. 2006. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob. Agents Chemother. 50:2941-2945.
18. Meletiadis, J., J. W. Mouton, J. F. Meis, and P. E. Verweij. 2003. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 47:106-117.
19. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129.
20. Rebuck, J. A., D. N. Fish, and E. Abraham. 2002. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 22:1216-1225.
21. Saballs, M., M. Pujol, F. Tubau, C. Pena, A. Montero, M. A. Dominguez, F. Gudiol, and J. Ariza. 2006. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 58:697-700.
22. Snyder, S., D. Z. D'Argenio, O. Weislow, J. A. Bilello, and G. L. Drusano. 2000. The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob. Agents Chemother. 44:1051-1058.
23. Talbot, G. H., J. Bradley, J. E. Edwards, Jr., D. Gilbert, M. Scheid, and J. G. Bartlett. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668.
24. Tam, V. H., A. Louie, T. R. Fritsche, M. Deziel, W. Liu, D. L. Brown, L. Deshpande, R. Leary, R. N. Jones, and G. L. Drusano. 2007. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J. Infect. Dis. 195:1818-1827.
25. Tam, V. H., P. S. McKinnon, R. L. Akins, G. L. Drusano, and M. J. Rybak. 2003. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob. Agents Chemother. 47:1853-1861.
26. Tam, V. H., A. N. Schilling, R. E. Lewis, D. A. Melnick, and A. N. Boucher. 2004. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob. Agents Chemother. 48:4315-4321.
27. Te Dorsthorst, D. T. A., P. E. Verweij, J. Meletiadis, M. Bergervoet, N. C. Punt, J. F. G. M. Meis, and J. W. Mouton. 2002. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob. Agents Chemother. 46:2982-2989.
28. Tod, M., O. Lortholary, D. Seytre, R. Semaoun, B. Uzzan, L. Guillevin, P. Casassus, and O. Petitjean. 1998. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob. Agents Chemother. 42:849-856.
29. Urban, C., S. Segal-Maurer, and J. J. Rahal. 2003. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin. Infect. Dis. 36:1268-1274.